Want to see AU:CU6 full AI Analyst Report?
Top Page
Clarity Pharmaceuticals Ltd.
(Sydney:CU6)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$2.50
â–˛(0.00% Upside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance—zero revenue in 2026, widening losses, and sustained negative operating/free cash flow that elevates funding and dilution risk. Technicals are mixed but still pressured versus longer-term moving averages, while valuation offers limited support due to negative earnings and no dividend yield.
Positive Factors
Debt-free balance sheet
The absence of reported debt lowers fixed financing obligations and reduces solvency risk while the company funds clinical development. This gives management more flexibility to allocate capital toward research, trials, and future commercialization.
Negative Factors
Revenue generation disruption
Zero reported revenue in the latest period leaves the business dependent on future clinical success, approvals, partnerships, or commercialization. The reversal from prior growth materially weakens near-term visibility into recurring revenue and the timing of operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of reported debt lowers fixed financing obligations and reduces solvency risk while the company funds clinical development. This gives management more flexibility to allocate capital toward research, trials, and future commercialization.
Read all positive factors
Clarity Pharmaceuticals Ltd. (CU6) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$850.63M
Dividend YieldN/A
Average Volume (3M)2.20M
Price to Earnings (P/E)―
Beta (1Y)2.52
Revenue GrowthN/A
EPS Growth-44.83%
CountryAU
Employees88
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.29
Shares Outstanding373,081,240
10 Day Avg. Volume1,853,350
30 Day Avg. Volume2,200,923
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.23
Price to Sales (P/S)0.00
P/FCF Ratio-8.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.80Price Target Upside172.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.3
Revenue Forecast (FY)AU$5.95M
Clarity Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranost...
How the Company Makes Money
Clarity Pharmaceuticals’ primary economic model is typical of a clinical-stage biopharmaceutical company: it invests in discovering and developing radiopharmaceutical candidates and seeks to generate future revenue primarily through commercializat...
Clarity Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 9.46M | 11.51M | 9.80M | 6.46M |
| Gross Profit | -283.53K | 9.46M | 11.51M | 9.70M | 6.41M |
| EBITDA | -118.62M | -68.91M | -44.65M | -34.20M | -30.15M |
| Net Income | -107.14M | -64.30M | -42.32M | -24.60M | -23.75M |
Balance Sheet | |||||
| Total Assets | 199.06M | 101.17M | 154.63M | 76.90M | 99.82M |
| Cash, Cash Equivalents and Short-Term Investments | 178.25M | 84.12M | 136.51M | 65.01M | 92.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 12.96M | 10.94M | 8.33M | 7.72M | 7.59M |
| Stockholders Equity | 186.11M | 90.23M | 146.30M | 69.18M | 92.24M |
Cash Flow | |||||
| Free Cash Flow | -92.85M | -54.95M | -43.74M | -27.55M | -13.53M |
| Operating Cash Flow | -92.55M | -54.77M | -43.24M | -27.50M | -13.31M |
| Investing Cash Flow | -84.92M | 51.99M | -55.31M | 3.15M | -26.71M |
| Financing Cash Flow | 192.96M | 2.21M | 115.21M | 231.58K | 86.93M |
Clarity Pharmaceuticals Ltd. Technical Analysis
Negative
2.50
Price Trends
2.40
Negative
2.54
Negative
2.96
Negative
Market Momentum
-0.01
Positive
42.53
Neutral
21.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CU6, the sentiment is Negative. The current price of 2.5 is below the 20-day moving average (MA) of 2.59, above the 50-day MA of 2.40, and below the 200-day MA of 2.96, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.53 is Neutral, neither overbought nor oversold. The STOCH value of 21.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CU6.
Clarity Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$5.22B | 111.36 | 7.11% | ― | 26.66% | 179.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$417.63M | -35.54 | -36.95% | ― | ― | -125.09% | |
49 Neutral | AU$343.48M | -42.11 | -42.35% | ― | 145.32% | 25.75% | |
45 Neutral | AU$850.63M | -7.69 | -51.15% | ― | ― | -44.83% | |
45 Neutral | AU$70.74M | -0.93 | -98.86% | ― | ― | -27.73% | |
42 Neutral | AU$43.38M | -0.58 | -144.24% | ― | -23.82% | 12.36% |
* Healthcare Sector Average
AU:CU6
Clarity Pharmaceuticals Ltd.
2.33
-0.76
-24.60%
AU:IMM
Immutep Ltd
0.05
-0.19
-79.18%
AU:SPL
Starpharma Holdings Limited
0.72
0.61
572.90%
AU:TLX
Telix Pharmaceuticals
15.27
0.96
6.71%
AU:RAC
Race Oncology Ltd.
2.24
1.02
83.61%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-62.96%
Clarity Pharmaceuticals Ltd. Corporate Events
Clarity Pharmaceuticals Lifts Revenue but Posts Wider Loss in FY26 Preliminary Results
Aug 27, 2026
Clarity Pharmaceuticals has released its Appendix 4E preliminary final report for the year ended 30 June 2026, showing revenue from ordinary activities rising 68% to $8.0 million. Despite the top-line growth, the company’s loss after tax wid...
State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Aug 12, 2026
State Street Corporation and several of its global asset management subsidiaries have lodged a notice that they have ceased to be substantial holders in Clarity Pharmaceuticals Ltd as of 10 August 2026. The change reflects an adjustment in their r...
State Street Group Ceases Substantial Holding in Clarity Pharmaceuticals
Aug 6, 2026
State Street Corporation and several of its asset management subsidiaries have lodged a notice that they have ceased to be a substantial holder in Clarity Pharmaceuticals Ltd. This change in relevant interest, recorded under section 671B of the Co...
Clarity Highlights SAR-bisPSMA Pipeline and Emphasises High-Risk, Early-Stage Profile
Aug 6, 2026
Clarity Pharmaceuticals used the Bioshares Biotech Summit to highlight its Australian-developed SAR-bisPSMA radiopharmaceutical platform and broader investigational pipeline, all of which remain unapproved by regulators such as the FDA and TGA. Th...
Clarity Posts Strong 67Cu-SAR-bisPSMA Data in SECuRE Prostate Cancer Trial
Aug 5, 2026
Clarity Pharmaceuticals has reported encouraging preliminary safety and efficacy data from the 8 GBq dose level of its 67Cu-SAR-bisPSMA therapy in the SECuRE trial for advanced prostate cancer. Among 19 participants, most of whom had bone metastas...
Clarity Pharmaceuticals Bolsters Cash, Manufacturing and Governance Ahead of Commercial Launch
Jul 31, 2026
Clarity Pharmaceuticals ended the June 2026 quarter with a cash balance of $178.3 million, more than 60% held in U.S. dollars to hedge its substantial American clinical, operational and commercial spending, though the stronger Australian dollar pr...
JPMorgan Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Jul 7, 2026
JPMorgan Chase Co. and its affiliates have notified Clarity Pharmaceuticals Ltd. that they have ceased to be a substantial holder in the company as of July 3, 2026. The change reflects adjustments across several JPMorgan entities engaged in secur...
Vanguard Cuts Stake Below Substantial Holder Threshold in Clarity Pharmaceuticals
Jul 6, 2026
Vanguard Group has notified Clarity Pharmaceuticals that it has ceased to be a substantial holder in the company as of 1 July 2026, reducing its voting power to 4.751%. The change in Vanguard’s relevant interest, set out in regulatory filing...
Clarity Pharmaceuticals Issues New Shares Following Option Exercise
Jul 1, 2026
Clarity Pharmaceuticals has issued 110,000 fully paid ordinary shares following the exercise of options, expanding its share capital without providing a disclosure document under the relevant provisions of the Corporations Act, while confirming co...
Clarity Pharmaceuticals Seeks ASX Quotation for Additional 110,000 Shares
Jul 1, 2026
Clarity Pharmaceuticals Ltd has applied for quotation on the ASX of 110,000 additional ordinary fully paid shares under its CU6 ticker, with the new securities issued on July 1, 2026. The issue, arising from the exercise or conversion of existing ...
Clarity’s SAR-bisPSMA data set to showcase prostate cancer advances at EANM 2026
Jun 29, 2026
Clarity Pharmaceuticals will present new data on its copper-based SAR-bisPSMA imaging and therapy agents at the European Association of Nuclear Medicine Congress 2026 in Vienna, underscoring the growing clinical profile of its prostate cancer port...
Clarity Pharmaceuticals marks 100-staff milestone as it builds radiopharmaceutical capabilities
Jun 25, 2026
Clarity Pharmaceuticals has reached a 100-employee milestone, reflecting rapid headcount growth of about 45% in the current financial year and a strong focus on talent in the U.S. and Australia. The company emphasises advanced qualifications, ongo...
Regal Partners exits substantial holding in Clarity Pharmaceuticals
Jun 25, 2026
Regal Partners Funds Management Pty Ltd and related entities have ceased to be substantial holders in Clarity Pharmaceuticals Ltd., after a series of on-market share sales between 17 and 23 June 2026. The disposals, which cumulatively reduced thei...
State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Jun 22, 2026
State Street Corporation and several of its asset management subsidiaries have lodged a notice that they have ceased to be a substantial holder in Clarity Pharmaceuticals Ltd as of 18 June 2026, under Section 671B of the Corporations Act. The chan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.